找化学品上960化工网!
960化工网

紫杉醇 | 33069-62-4

紫杉醇
Paclitaxel
33069-62-4
C47H51NO14
853.906
如需查看该化合物的详细结构式,mol文件,smile,InChi 请点击:紫杉醇结构式
紫杉醇MSDS
24277878
紫杉醇价格
简介
Paclitaxel 是一种天然抗肿瘤药,可稳定微管蛋白 (tubulin) 的聚合。Paclitaxel 可导致有丝分裂停滞和诱导细胞凋亡 (apoptosis),最终导致细胞死亡。Paclitaxel 还可诱导细胞自噬 (autophagy)。
名称和标识符
MDL MFCD00869953
InChIKey RCINICONZNJXQF-MZXODVADSA-N
Inchi InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
SMILES O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O
BRN 1420457
别名信息
- 中文别名 -
  • 紫杉醇
  • TAXOL紫杉醇
  • 合成紫杉醇
  • 浆果赤霉素III
  • 泰素
  • 紫杉醇 GMP
  • Paclitaxel 紫杉醇
  • 半合成紫杉醇
  • 半合成紫杉醇峰鉴别 EP标准品
  • 半合成紫杉醇系统适应性 EP标准品
  • 醋氨己酸锌
  • 天然紫杉醇
  • 猪去氧胆酸
  • 紫杉醇 EP标准品
  • 紫杉醇 USP标准品
  • 紫杉醇 标准品
  • 紫杉醇(半合成)
  • 紫杉醇(标准品)
  • 紫杉醇 植物提取物,标准品,对照品
  • 紫杉醇[半合成]
  • 紫杉醇峰鉴别 EP标准品
  • 紫素
  • 红豆杉提取物
  • 特素
  • 紫杉醇 &nbsp
  • 天然紫杉醇提取物功效
  • 泰素,紫素
  • 紫杉醇,太素,特素,紫素
  • Paclitaxel 紫杉醇 试剂级,98%
  • 紫杉醇(分析标准品)
  • 天然紫杉醇峰鉴别
- 英文别名 -
  • Paclitaxel
  • N-BENZYL-BETA-PHENYLISOSERINE ESTER
  • PACLITAXEL, TAXUS BREVIFOLIA
  • PACLITAXEL, TAXUS SPECIES
  • PACLITAXOL
  • TAXOL(TM)
  • taxol a
  • TAXOL EQUIVALENT
  • PACLITAXEL(P)
  • PACLITAXEL(P) PrintBack
  • PACLITAXEL(RG)
  • Paclitaxel(Taxol)
  • PACLITAXEL,Taxol
  • Taxol
  • &nbsp
  • (-)-Paclitaxel
  • ABI 007
  • Capxol
  • DHP 107
  • EMPAC
  • NK 105
  • Onxal
  • taxal
  • TAXUS
  • Desmocap11
  • 7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete benzenepropanoic acid deriv.
  • BSPBio_002614
  • IDI1_000441
  • Spectrum5_001491
  • KBioGR_000492
  • KBio2_002016
  • Pharmakon1600-01503908
  • NCGC00024995-10
  • Spectrum4_001197
  • HMS3676G15
  • HMS1922K08
  • BRD-A28746609-001-05-7
  • KBio2_005628
  • AKOS015960460
  • UPCMLD-DP108:001
  • Bio1_000362
  • SDCCGMLS-0066823.P001
  • SR-01000597377-1
  • KBio3_000904
  • AB00172230_04
  • SR-01000597377
  • LMPR0104390001
  • KBio1_000441
  • NSC-758645
  • SDCCGSBI-0051168.P004
  • Bio2_000416
  • [2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-(Benzoylamino)-?-hydroxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid
  • BP-23960
  • T 7402
  • HMS1792J13
  • SPECTRUM1503908
  • HMS1362J13
  • IDI1_002171
  • NCGC00024995-06
  • KBio3_000903
  • AB00172230-03
  • KBioSS_002016
  • LP01201
  • NCGC00024995-03
  • BRD-A28746609-001-04-0
  • SCHEMBL788187
  • NCGC00024995-43
  • NCGC00024995-05
  • AKOS015894977
  • HMS501G03
  • CCG-40266
  • KBioSS_000492
  • CHEMBL48
  • NS00003967
  • KBio2_003060
  • NCGC00024995-08
  • AC-675
  • Bio2_000896
  • NINDS_000441
  • KBioGR_001893
  • Paclitaxel (Taxol)
  • NCGC00024995-13
  • NCGC00024995-02
  • KBio2_004584
  • HMS2093K15
  • HMS3412G15
  • AS-11004
  • Spectrum_001536
  • NSC758645
  • SMP1_000228
  • SBI-0051168.P003
  • BSPBio_001152
  • EU-0101201
  • s1150
  • NCGC00024995-07
  • P1632
  • KBio3_001834
  • UPCMLD-DP108:002
  • C07394
  • NCGC00024995-09
  • NCGC00024995-04
  • Lopac0_001201
  • SPBio_000943
  • BRD-A28746609-001-02-4
  • DivK1c_000441
  • KBio2_000492
  • Spectrum2_000872
  • KBio2_007152
  • Bio1_000851
  • Spectrum3_001057
  • Bio1_001340
  • AB00172230_05
  • Probes2_000350
  • HMS1990J13
  • Genexol-PM
  • PACLITAXEL [EP MONOGRAPH]
  • ABI-007
  • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-Tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (alphaR,betaS)-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate
  • 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXAHYDROXY-TAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYL-ISOSERINE
  • OncoGel
  • Anzatax
  • BRD-K62008436-001-03-1
  • HMS3712O12
  • 3PPC5TL76P
  • Nanotaxel
  • KBioGR_002509
  • CAS-33069-62-4
  • L01CD01
  • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,
  • CHEBI:45863
  • Cypher select
  • (NAB)-Paclitaxel
  • AB00513812-03
  • ABRAXANE COMPONENT PACLITAXEL
  • 5beta,20-Epoxy-1,2 alpha, 4,7beta, 10beta, 13alpha-hexahydroxy tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine
  • Cynviloq
  • NCGC00164367-04
  • MBT 0206
  • CHEMBL428647
  • [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
  • Paclitaxel-SSMM-VIP
  • Ebetaxel
  • NCGC00164367-01
  • (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
  • HMS2090D07
  • PACLITAXEL [JAN]
  • BRD-K62008436-001-05-6
  • Paclitaxel,(S)
  • SMR000857385
  • 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
  • PACLITAXEL [USP MONOGRAPH]
  • NSC-125973
  • DRG-0190
  • Paclitaxel [USAN:USP:INN:BAN]
  • Bris Taxol
  • Paclical
  • P-SSMM-VIP
  • Taxus Express
  • PACLITAXEL [VANDF]
  • SDP-013
  • BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-
  • GS-6554
  • KBio2_002509
  • D00491
  • Yewtaxan
  • nab-paclitaxel
  • (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
  • SCHEMBL3976
  • Q-201533
  • Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder
  • Q423762
  • Genaxol
  • Pacligel
  • Paclitaxel, from Taxus yannanensis, powder
  • Infinnium
  • PACLITAXEL [GREEN BOOK]
  • Taxol (Paclitaxel)
  • CCRIS 8143
  • P88XT4IS4D
  • Taxol (TN) (Bristol Meyers)
  • Paclitaxol
  • PACLITAXEL [WHO-DD]
  • BIDD:PXR0046
  • HSDB 6839
  • PACLITAXELPACLITAXEL
  • MLS002695976
  • Genetaxyl
  • ,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
  • 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
  • DTS-301
  • TAX-11-EN-9-ONE, 5BETA,20-EPOXY-1,2ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE
  • DTXCID603413
  • PACLITAXEL (EP MONOGRAPH)
  • Tax-11-en-9-one,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • EN300-117275
  • Nanoxel
  • PACLITAXEL [MART.]
  • Paclitaxel, from semisynthetic (from Taxus sp.), >=97%
  • TaxAlbin
  • PACLITAXEL [HSDB]
  • (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12
  • DHP-208
  • KBio3_002987
  • Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard
  • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2a-alpha,4-beta,4a-beta,6-beta,9-alpha(alpha-R*,beta-S*),11-alpha,12-alpha,12a-alpha, 12b-alpha))-
  • Coroflex Please
  • NCGC00164367-03
  • PACLITAXEL [MI]
  • Taxol A
  • AKOS015969673
  • Tocosol Paclitaxel
  • Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha- hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate
  • Tox21_112107
  • Plaxicel
  • 1203669-79-7
  • PACLITAXEL (MART.)
  • IG 001
  • MFCD00869953
  • EndoTAG-1
  • Sindaxel
  • NCGC00164367-10
  • Paclitaxel, European Pharmacopoeia (EP) Reference Standard
  • BMS-181339-01
  • paclitaxelum
  • Pacliex
  • HY-B0015
  • M02242
  • (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
  • AB00513812-02
  • PACLITAXEL (USP-RS)
  • NK-105
  • Cyclopax
  • PACLITAXEL (USP MONOGRAPH)
  • Prestwick3_000155
  • Taxus Liberte
  • AKOS007930675
  • Paclitaxel, Taxus brevifolia
  • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-
  • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate
  • ORAXOL COMPONENT PACLITAXEL
  • NSC-745099
  • HMS2095O12
  • Liposome-entrapped paclitaxel easy-to-use
  • N88686
  • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate
  • EndoTAG 1
  • SR-01000075350
  • ABI-007 COMPONENT PACLITAXEL
  • NSC 125973
  • PACLITAXEL (USP IMPURITY)
  • BMS-181339
  • ANX-513
  • CS-1145
  • Taxol, Bris
  • PACLITAXEL IMPURITY L [EP IMPURITY]
  • RCINICONZNJXQF-MZXODVADSA-N
  • Paclitaxel protein-bound particles for injectable suspension (albumin-bound)
  • 33069-62-4
  • Nova-12005
  • Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-
  • PACLITAXEL [INN]
  • Paxene
  • 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
  • PACLITAXEL [ORANGE BOOK]
  • BDBM50001839
  • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13
  • 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • Xorane
  • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • KBio2_005077
  • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-
  • NCGC00164367-05
  • EmPAC
  • -cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(aR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-
  • MEGxp0_001940
  • Paxoral
  • (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4,10-Diacetoxy-2-benzoyloxy-5,20-epoxy-1,7-dihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate
  • Paclitaxel, Pharmaceutical Secondary Standard
  • Certified Reference Material
  • MLS002154218
  • SR-01000075350-3
  • LEP-ETU
  • PACLITAXEL [USAN]
  • SR-01000075350-7
  • 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • QW-8184
  • Paclitaxel, United States Pharmacopeia (USP) Reference Standard
  • DHP-107
  • BPBio1_000320
  • MPI-5018
  • BRD-K62008436-001-22-1
  • [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate
  • Taxus
  • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-
  • Zisu
  • MBT-0206
  • NCI60_000601
  • Paxceed
  • Taxus stent
  • CCG-220155
  • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H
  • 4alpha,10beta-bis(acetyloxy)-13alpha-((2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy)-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
  • UNII-P88XT4IS4D
  • Paclitaxel, Antibiotic for Culture Media Use Only
  • [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate
  • Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-
  • DTXSID9023413
  • Intaxel
  • AKOS025312303
  • NSC125973
  • ACon1_002231
  • Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard
  • Padexol
  • PACLITAXEL [EMA EPAR]
  • Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-
  • Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard
  • Paclitaxel
  • 5beta,20-Epoxy-1,7beta-dihydroxy-9-oxotax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]
  • Taxol
  • Docetaxel Anhydrous Impurity F
  • Docetaxel Impurity F
  • Abraxane (albumin-bound suspension)
  • DB01229
  • KBio2_007645
  • cMAP_000068
  • Paclitaxel (taxus canadensis)
  • QW 8184
  • Abraxane
  • BMS 181339-01
  • PACLITAXEL [USP-RS]
  • SR-01000075350-9
  • OAS-PAC-100
  • GTPL2770
  • ABI 007 COMPONENT PACLITAXEL
  • Genexol
  • Paclitaxel, From Taxus brevifolia, 95%
  • NCGC00164367-02
  • BSPBio_000290
  • SR-01000075350-6
  • Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI)
  • 1ST000431
  • Paclitaxel (JAN/USP/INN)
  • Abraxane (TN)
  • SR-01000075350-1
  • HMS2231A16
  • 4,7beta,10beta-tris(acetyloxy)-13alpha-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
  • LipoPac
  • ,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)- (9CI)
  • NAB-PACLITAXEL COMPONENT PACLITAXEL
  • TAXOL (TN)
  • (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate
  • Paclitaxel (USAN:USP:INN:BAN)
  • Onxol
  • Mitotax
  • KBioSS_002517
  • AB00513812
  • NSC745099
  • Abraxane I.V. Suspension
  • TAX-11-EN-9-ONE, 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXA-HYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE
  • PACLITAXEL [USP IMPURITY]
  • Epitaxol
  • MLS001097642
  • SMR000578108
  • TAXOL
  • 7-epi-Taxol
  • taxol
  • Taxol
  • Paclitaxel
  • MLSMR
  • Paclitaxel natural for peak identification
物化性质
实验特性
LogP 4.12660
PSA 221.29000
Merck 6982
折射率 -49 ° (C=1, MeOH)
沸点 957.1°C at 760 mmHg
熔点 213-216 ºC
闪点 9℃
溶解度 methanol: 50 mg/mL, clear, colorless
颜色与性状 Powder
稳定性 Stable. Incompatible with strong oxidizing agents. Combustible.
溶解性 未确定
最大波长(λmax) 227(MeOH)(lit.)
比旋光度 -49° - -54° (c=1, MeOH)
密度 0.2
计算特性
精确分子量 853.33100
氢键供体数量 4
氢键受体数量 15
可旋转化学键数量 15
同位素质量 853.33095530 g/mol
重原子数量 62
复杂度 1790
同位素原子数量 0
确定原子立构中心数量 11
不确定原子立构中心数量 0
确定化学键立构中心数量 0
不确定化学键立构中心数量 0
共价键单元数量 1
疏水参数计算参考值(XlogP) 2.5
互变异构体数量 6
表面电荷 0
拓扑分子极性表面积 221
分子量 853.9
国际标准相关数据
EINECS 205-285-7
海关数据
海关编码 2932999021
海关数据

中国海关编码:

2932999021
生产方法和用途
用途 紫杉醇主要适用于卵巢癌和乳腺癌,对肺癌、大肠癌、黑色素瘤、头颈部癌、淋巴瘤、脑瘤也都有一定疗效。
生产方法 用途
专业数据库参考
PubChemId 24277878
参考资料
Reaxys RN 1420457
Beilstein 18(5)5,622
化合物详情(旧版)

紫杉醇物理化学性质

外观性状:白色晶体。
熔点 :213 °C (dec.)(lit.)
折射率 :-49 ° (C=1, MeOH)
储存条件 :2-8°C
溶解度 :methanol: 50 mg/mL, clear, colorless
form :powder
color :white
Merck :6982

概述 

   1963年美国化学家瓦*(M.C. Wani)和沃尔(Monre E. Wall)首次从一种生长在美国西部大森林中称谓太平洋杉(Pacific Yew)树皮和木材中分离到了紫杉醇的粗提物。在筛选实验中,Wani和 Wall发现紫杉醇粗提物对离体培养的鼠肿瘤细胞有很高活性,并开始分离这种活性成份。由于该活性成份在植物中含量极低,直到1971年,他们才同杜克(Duke)大学的化学教授姆克法尔(Andre T. McPhail)合作,通过X-射线分析确定了该活性成份的化学结构,一种三环二萜化合物,并把它命名为紫杉醇(taxol)。紫杉醇是一种从裸子植物红豆杉的树皮分离提纯的天然次生代谢产物,经临床验证,具有良好的抗肿瘤作用,特别是对癌症发病率较高的卵巢癌、子宫癌和乳腺癌等有特效。
    紫杉醇是近年国际市场上最热门的抗癌药物,被认为是人类未来20年间最有效的抗癌药物之一。近年来地球人口和癌发率呈爆发性增长,对紫杉醇的需求量亦明显增大。目前临床和科研所需的紫杉醇主要是从红豆杉中直接提取,由于紫杉醇在植物体中的含量相当低(目前公认含量最高的短叶红豆杉树皮中也仅有0.069%),大约13.6kg的树皮才能提出1g的紫杉醇,治疗一个卵巢癌患者需要3-12棵百年以上的红豆杉树,也因此造成了对红豆杉的大量砍伐,致使这种珍贵树种已濒临灭绝。加之紫杉本身资源很贫乏,而且红豆杉属植物生长缓慢,这对紫杉醇的进一步开发利用造成了很大的困难。化学合成尽管已完成,但由于需要的条件严格,产量低,经费高,不具有产业意义。现在紫杉醇的半合成方法已比较成熟,被认为是除人工种植外,扩大紫杉醇来源的有效途径。半合成法可以更大限度地利用植物资源,但与直接提取紫杉醇的办法并无本质上区别,需要消耗大量红豆杉树木,仍然不能从根本上解决植物源匮乏的问题。显然从红豆杉植物组织中提取紫杉醇受到极大限制,寻找获取紫杉醇的新途径具有十分重要的意义。

紫杉醇产品用途

用途一:广谱抗肿瘤植物药,用于卵巢癌、乳腺癌等。

用途二:广谱抗肿瘤植物药,用于治疗卵巢癌、乳腺癌等病症

用途三:;抗肿瘤药。用于治疗转移性乳腺癌和转移性卵巢癌。广谱抗肿瘤植物药,用于治疗卵巢癌、乳腺癌等病症

适应症

   治疗卵巢癌和铂类等已有抗药性的顽固性卵巢癌、乳腺癌有良好效果,对治疗前列腺癌、、头颈部癌、食管癌、生殖细胞肿瘤、子宫内膜癌、淋巴瘤、膀胱癌、上消化道癌、小细胞性和非小细胞性肺癌前景良好。 

高效分离纯化紫杉醇的方法

    它包括a、萃取,以红豆杉为原料获得含有紫杉醇的提取物;b、去除胶质,除去提取物中的胶质杂质;c、分离纯化。  

 其特征在于:紫杉醇生产工艺如下:红豆杉树皮粉碎(越细越好),85%~95%酒精(料液比是多少?)35-55℃热回流浸提三次(每一次需要多少时间?),50-70℃真空减压浓缩至热测比重1.1~1.2g/ml,氯仿萃取,萃取液浓缩成膏状,得紫杉醇含量1%氯仿膏,将紫杉醇含量1%氯仿膏加氯仿溶解完全,加硅胶搅拌均匀,凉干,过筛,填装到层析柱中,氯仿-甲醇梯度洗脱,TLC检测,分段合并浓缩,得紫杉醇含量5~8%半成品,将紫杉醇含量5~8%半成品加丙酮溶解完全,加硅胶搅拌均匀,凉干,过筛,填装到层析柱中,丙酮-石油醚梯度洗脱,TLC检测,分段合并浓缩,得紫杉醇含量20~25%半成品,用丙酮-石油醚系统结晶3~4次,抽滤,50℃真空减压干燥,得紫杉醇含量75~80%半成品,16Mpa压力层析分离,TLC检测,分段合并浓缩,目标段浓缩物丙酮-石油醚结晶,抽滤,干燥,得紫杉醇含量≥99.5%成品; 去除胶质的过程为:高压硅胶层析柱层析去除胶质,同时将紫杉烷化合物分离为紫杉醇、三尖杉宁碱、7-表紫杉醇3部分。


针剂使用注意事项

1.血液学毒性:为限制剂量提高的主要因素,一般在白细胞低于1500/mm3时应辅助应用G-CSF,血小板低于30,000/mm3时应输成分血。

2.过敏反应:除了预处理外,如只有轻微症状如面潮红、皮肤反应、心率略快、血压稍降可不必停药,可将滴速减慢。但如出现严重反应如血压低、血管神经性水肿、呼吸困难、全身寻麻疹,应停药并给以适当处理。有严重过敏的病人下次不宜再次应用紫杉醇治疗。

3.神经系统:最常见为指趾麻木。有约4%的病人,特别是高剂量时可出现明显的感觉和运动障碍及腱反射减低。曾有个别报告在滴注时发生癫痫大发作。

4.心血管:一过性心动过速和低血压较常见,一般不需处理。但在滴注的第一小时应严密观察,以后除有严重传导阻滞的病人不必每小时观察一次。

5.关节和肌肉:半数左右的病人在用药后2~3天会感到关节和肌肉疼痛,与所用剂量相关。一般在几天内恢复。在给予G-CSF的病人肌肉痛会加重。

6.肝胆系统:由于紫杉醇大部由胆汁中排出,对有肝胆疾病的病人应谨慎观察。在数千例的资料中约8%的病人有胆红素升高,23%的病人碱性磷酸酶升高,18%有谷草转氨酶升高。但目前尚无资料说明紫杉醇对肝功有严重损害。

7.其他:消化道反应虽常见但一般不重,少数可有腹泻和粘膜炎。轻度脱发也较常见。 

紫杉醇制备方法

   由紫杉树皮、木质根部、树叶、嫩枝和幼苗中分离提纯的天然产物,含量以树皮中最高。紫杉在中国植物学志中的学名为红豆杉,植物分类归裸子植物亚门,松杉纲,紫杉目,红豆杉科,红豆杉属。红豆杉科含5属23种,我国有4属12种和1变种,分别为西藏红豆杉或喜马拉雅红豆杉(Taxus wallichinanaZucc.),云南红豆杉(Taxus yunnanensis),南方红豆杉(Taxus chinensis vat.Mairei)和东北红豆杉(Taxus cuspidata)。分布在西藏、云南、贵州、四川、广西、广东、湖南、湖北、江西、福建、浙江、安徽、河南、山西、陕西、甘肃和吉林山区。
   由红豆杉属植物的树皮或树叶中提取。红豆杉树皮或树叶阴干,磨细后,和95%乙醇提取。提取液浓缩至干,剩余物用水和二氯甲烷混合搅拌。静置分出有机层,水层用二氯甲烷提取多次。提取液和有机层合并后,浓缩至干。剩余物溶入醋酸乙酯-甲醇(3:1),和新鲜硅藻土拌和后,减压蒸除溶剂。剩余的粉末进行快速柱层析,先用己烷洗,后用二氯甲烷洗脱。收集后者,减压蒸去二氯甲烷。剩余物溶于醋酸乙酯,用70套(每套3~4根)装有硅胶的中压快速色谱柱进行层析,用不同配比的己烷-丙酮洗脱。收集含产物的组分,浓缩。剩余物再经装有硅胶的中压快速色谱柱纯化,用不同配比的甲醇-二氯甲烷洗脱。收集含产物的组分,减压浓缩至于。剩余物再经制备型高效液相色谱仪分离,得到的产物再用含水甲醇重结晶2次,即得紫杉醇纯品。产率:树皮0.028%,树叶0.0088%。收率:树皮93.3%,树叶88%。熔点212~214℃,[α]D20-49°(1%,氯仿)。
   中国红豆杉茎皮经粉碎,阴干后,用1%柠檬酸水溶液浸泡24h后开始渗漉。用二氯甲烷萃取渗漉液,萃取液干燥后,浓缩,真空抽干。用硅胶进行2次柱层析,收集的流出液中含有紫杉醇和三尖杉宁碱。基于它们侧链结构的不同,把它们溶于四氯化碳中加溴,只对三尖杉宁碱进行溴化,再经硅胶柱层析,可得只含紫杉醇的流出液,经处理后,得紫杉醇精品,含量99.19%,收率4.5×10-5,回收率70%。

紫杉醇的分离纯化

  它包括a、萃取,以红豆杉为原料获得含有紫杉醇的提取物;b、去除胶质,除去提取物中的胶质杂质;c、分离纯化。
  其特征在于:紫杉醇生产工艺如下:红豆杉树皮粉碎(越细越好),85%~95%酒精(料液比是多少?)35-55℃热回流浸提三次(每一次需要多少时间?),50-70℃真空减压浓缩至热测比重1.1~1.2g/ml,氯仿萃取,萃取液浓缩成膏状,得紫杉醇含量1%氯仿膏,将紫杉醇含量1%氯仿膏加氯仿溶解完全,加硅胶搅拌均匀,凉干,过筛,填装到层析柱中,氯仿-甲醇梯度洗脱,TLC检测,分段合并浓缩,得紫杉醇含量5~8%半成品,将紫杉醇含量5~8%半成品加丙酮溶解完全,加硅胶搅拌均匀,凉干,过筛,填装到层析柱中,丙酮-石油醚梯度洗脱,TLC检测,分段合并浓缩,得紫杉醇含量20~25%半成品,用丙酮-石油醚系统结晶3~4次,抽滤,50℃真空减压干燥,得紫杉醇含量75~80%半成品,16Mpa压力层析分离,TLC检测,分段合并浓缩,目标段浓缩物丙酮-石油醚结晶,抽滤,干燥,得紫杉醇含量≥99.5%成品;
  去除胶质的过程为:高压硅胶层析柱层析去除胶质,同时将紫杉烷化合物分离为紫杉醇、三尖杉宁碱、7-表紫杉醇3部分。

紫杉醇计算用化学数据

疏水参数计算参考值(XlogP):2.5
氢键供体数量:4
氢键受体数量:14
可旋转化学键数量:14
互变异构体数量:6
准确质量:853.330955
同位素质量:853.330955
拓扑分子极性表面积(TPSA):221
重原子数量:62
形式电荷:0
复杂度:1790
同位素原子数量:0
确定原子立构中心数量:11
不确定原子立构中心数量:0
确定化学键立构中心数量:0
不确定化学键立构中心数量:0
共价键单元数量:1

扩展阅读
紫杉醇 http://www.biopurify.cn/p-3145.html
产品用途
广谱抗肿瘤植物药,用于治疗卵巢癌、乳腺癌等病症
紫杉醇推荐生产厂家
960化工网为您提供紫杉醇专业化合物百科信息,包括中文名,英文名,分子式,分子量,以及该化合物的CasNo.:33069-62-4,和相关理化性质;并提供了优质生产厂家信息包括厂家名称和联系方式等;| WAP 版:33069-62-4
平台客服 平台客服

平台在线客服